




Life Sciences & Health Care Quarterly Update

Q1 2021

Breaking the Cost Curve

Deloitte Corporate Finance expects that health spending as a percentage of GDP will decelerate over the next 20 years

In 2019, health care spending in the United States topped \$3.8 trillion dollars—nearly 18% of GDP. Prior to the COVID-19 pandemic, the CMS had projected health spending would continue to grow 5.3% annually, reaching nearly \$6.2 trillion by 2028. If those increases were to continue unabated over the next 20 years, health spending could reach a staggering \$11.8 trillion by 2040. Although the pandemic caused some people to defer care throughout much of 2020, a rebound and then continuation of the trends beyond 2021 would drive health care spending to historic levels in the coming years.⁽¹⁾

The continued upward trend, however, is unlikely to endure, according to models developed by Deloitte health care actuaries in collaboration with Deloitte health care sector leaders.⁽¹⁾ Deloitte anticipates that **emerging technologies, an ability to cure and prevent disease** (or detect disease in the earliest stages), and **highly engaged consumers will lead to a deceleration of health spending between now and 2040.**⁽¹⁾

Deloitte actuaries expect three realities will take shape by 2040:⁽¹⁾

#1: \$3.5 trillion well-being dividend

By 2040, Deloitte estimates health spending to reach \$8.3 trillion. The \$3.5 trillion difference between Deloitte and CMS models is driven by a “well-being dividend,” namely the return on investment for **tools, systems, or protocols** that help consumers to take an active role in their health and well-being.

#2: Shift in spending

New-generation well-being activities will likely **empower consumers to monitor their health** through technologies that can **sense early signals of disease in asymptomatic people**, and address drivers of health early.




#3: New health economy will drive 85% of revenue

Three major changes will likely impact incumbent health care stakeholders, driving more revenue, including:

1. The end of the general hospital as we know it.
2. The slowdown of mass-produced biopharma.
3. A seismic shift in the way health care is financed.

Health Care Spending Based on Future of Health Trends⁽¹⁾



In this update

- Healthcare innovations and consumer behavior expected to spur changes in overall health care spending mix over the next 20 years.

Also:

- Selected recent Life Sciences & Health Care (LSHC) M&A transactions
- LSHC sector breakdown and analysis
- Selected macroeconomic and sector data

Who we are

Deloitte Corporate Finance LLC (DCF) is a leading global middle market M&A advisor. DCF's professionals have extensive knowledge of and experience in the Life Sciences & Health Care space.

LSHC contacts

Simon Gisby

Managing Director
sgisby@deloitte.com
+1 (212) 436-2495

Doug Bolt


Managing Director
dbolt@deloitte.com
+1 (704) 731-7219

Source:

⁽¹⁾ Deloitte; “Breaking the cost curve: Deloitte predicts health spending as a percentage of GDP will decelerate over the next 20 years.” February 8, 2021.

Q2 2020 US LSHC M&A aggregate transaction value ⁽¹⁾⁽ⁱ⁾

Aggregate transaction value (\$ in millions)

**Q2 2020 US LSHC M&A activity deal list ⁽²⁾⁽ⁱ⁾**

Date announced	Status	Sub-sector	Target	Buyer	Size (\$MM) transaction
4-Jan-21	Closed	Medical Devices	Straight Smile, LLC	DENTSPLY SIRONA Inc. (NasdaqGS:XRAY)	\$1,072.0
4-Jan-21	Announced	Managed Health Care	Magellan Health, Inc. (NasdaqGS:MGLN)	Centene Corporation (NYSE:CNC)	3,269.5
4-Jan-21	Closed	Technology	Distributed Bio, Inc.	Charles River Laboratories International, Inc. (NYSE:CR)	104.0
5-Jan-21	Closed	Services	BioTheragnostics, Inc.	Hologic, Inc. (NasdaqGS:HOLX)	230.0
6-Jan-21	Announced	Technology	Change Healthcare Inc. (NasdaqGS:CHNG)	Optum, Inc.	13,685.3
6-Jan-21	Closed	Life Sciences	Woodstock Sterile Solutions	SK Capital Partners	400.0
8-Jan-21	Closed	Life Sciences	Oncocoetics, Inc.	Chimerix, Inc. (NasdaqGM:CMRX)	442.4
12-Jan-21	Closed	Life Sciences	Kashiv Specialty Pharmaceuticals, LLC	Amneal Pharmaceuticals, L.L.C.	108.0
12-Jan-21	Announced	Medical Devices	Cantel Medical Corp. (NYSE:CMD)	STERIS plc (NYSE:STE)	4,912.5
19-Jan-21	Closed	Medical Devices	Capsule Technologies, Inc.	Koninklijke Philips N.V. (ENXTAM:PHIA)	635.0
19-Jan-21	Closed	Medical Devices	Mesa Biotech, Inc.	Thermo Fisher Scientific Inc. (NYSE:TMO)	550.0
20-Jan-21	Closed	Medical Devices	Cardiva Medical, Inc.	Haemonetics Corporation (NYSE:HAE)	624.9
20-Jan-21	Closed	Technology	Mimic Technologies, Inc.	Surgical Science Inc.	33.6
21-Jan-21	Closed	Technology	Preventice Solutions, Inc.	Boston Scientific Corporation (NYSE:BSX)	950.0

Note:

i) Only US deals with reported transaction size greater than \$30MM listed.

Q2 2020 US LSHC M&A activity deal list ⁽¹⁾ (i)

Date announced	Status	Sub-sector	Target	Buyer	Size (\$MM) transaction
1-Feb-21	Closed	Life Sciences	Viela Bio, Inc.	Horizon Therapeutics USA, Inc.	3,043.9
1-Feb-21	Closed	Services	Recover Health, Inc.	Aveanna Healthcare Holdings Inc. (NasdaqGS:AVAH)	61.0
2-Feb-21	Announced	Life Sciences	Genopis Inc.	Wacker Chemie AG (XTRA:WCH)	42.1
3-Feb-21	Closed	Life Sciences	Decipher Biosciences, Inc.	Veracyte, Inc. (NasdaqGM:VCYT)	669.2
8-Feb-21	Closed	Services	CRH Medical Corporation (TSX:CRH)	WELL Health Technologies Corp. (TSX:WELL)	426.2
11-Feb-21	Announced	Life Sciences	E-Mo Biotech Holding Inc.	Fuse Biotech Inc.	100.0
16-Feb-21	Closed	Services	Ashion Analytics, LLC	Exact Sciences Corporation (NasdaqCM:EXAS)	141.5
16-Feb-21	Closed	Technology	rfxcel Corporation	Antares Vision, Inc.	150.0
17-Feb-21	Closed	Life Sciences	Cognate BioServices, Inc.	Charles River Laboratories International, Inc. (NYSE:CR)	875.0
18-Feb-21	Closed	Technology	Healthmode, Inc.	Mind Medicine (MindMed) Inc. (OTCPK:MED.F)	33.2
23-Feb-21	Closed	Life Sciences	Guide Therapeutics, LLC	Beam Therapeutics Inc. (NasdaqGS:BEAM)	440.0
24-Feb-21	Announced	Life Sciences	PRA Health Sciences, Inc. (NasdaqGS:PRAH)	ICON Public Limited Company (NasdaqGS:ICLR)	12,742.0
24-Feb-21	Closed	Medical Devices	Simplify Medical, Inc.	NuVasive, Inc. (NasdaqGS:NUVA)	199.0
25-Feb-21	Closed	Life Sciences	Pandion Therapeutics, Inc.	Merck Sharp & Dohme Corp.	1,813.1
26-Feb-21	Announced	Life Sciences	Silicon Therapeutics LLC	Roivant Sciences, Inc.	450.0
1-Mar-21	Announced	Life Sciences	ANP Technologies, Inc.	Sorrento Therapeutics, Inc. (NasdaqCM:SRNE)	100.0
1-Mar-21	Closed	Life Sciences	25 U.S. Based Plasma Donation Centers of BPL Plasma, Inc	Biomat USA, Inc.	370.0
2-Mar-21	Closed	Life Sciences	Resolution Bioscience, Inc.	Agilent Technologies, Inc. (NYSE:A)	695.0
3-Mar-21	Closed	Medical Devices	Asuragen, Inc.	Bio-Techne Corporation (NasdaqGS:TECH)	320.0
4-Mar-21	Closed	Life Sciences	Five Prime Therapeutics, Inc.	Amgen Inc. (NasdaqGS:AMGN)	1,939.1
9-Mar-21	Closed	Life Sciences	GigaGen, Inc.	Grifols, S.A. (BME:GRF)	80.0
9-Mar-21	Announced	Medical Distributors	Novitium Pharma LLC	ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP)	210.8
9-Mar-21	Announced	Life Sciences	Maverick Therapeutics, Inc.	Takeda Pharmaceutical Company Limited (TSE:4502)	525.0
10-Mar-21	Closed	Life Sciences	MatTek Corporation	Cellink AB (publ) (OM:CLNK B)	72.0
12-Mar-21	Announced	Medical Devices	Cordis Corporation	Hellman & Friedman LLC	1,000.0
15-Mar-21	Closed	Medical Devices	GenMark Diagnostics, Inc.	Roche Holding AG (SWX:ROG)	1,950.4
15-Mar-21	Closed	Services	Apollo Medical Holdings, Inc. (NasdaqCM:AMEH)	Medical Practice Holding Company, LLC	40.1
18-Mar-21	Closed	Services	Bazelet Health Systems, Inc.	Neon Bloom, Inc. (OTCPK:NBCO)	216.0
22-Mar-21	Closed	Technology	d-Wise Technologies, Inc.	Instem plc (AIM:INS)	31.0
22-Mar-21	Announced	Medical Devices	7D Surgical, Inc.	SeaSpine Holdings Corporation (NasdaqGS:SPNE)	109.5
23-Mar-21	Announced	Life Sciences	Renovacor, Inc.	Chardan Healthcare Acquisition 2 Corp. (AMEX:CHAQ)	85.2
24-Mar-21	Closed	Technology	Trapelo Health	NeoGenomics, Inc. (NasdaqCM:NEO)	60.0
24-Mar-21	Closed	Medical Devices	Mayfair Technology Limited Liability Company	Mettler-Toledo LLC	205.0
30-Mar-21	Announced	Medical Devices	Alydia Health, Inc.	Organon & Co.	240.0
30-Mar-21	Closed	Services	Access Physicians Management Services Organization, LLC	SOC Telemed, Inc. (NasdaqGS:TLMD)	221.1
30-Mar-21	Closed	Medical Distributors	Bioness Inc.	Bioventus Inc. (NasdaqGS:BVS)	110.0
30-Mar-21	Announced	Life Sciences	Rodeo Therapeutics Corporation	Amgen Inc. (NasdaqGS:AMGN)	721.0

Note:

i) Only US deals with reported transaction size greater than \$30MM listed.

LSHC sector breakdown: financial detail ⁽¹⁾

	Enterprise value (\$MM)	Three-year revenue CAGR	LTM			EV / LTM	
			Revenue (\$MM)	EBITDA (\$MM)	EBITDA margin	Revenue	EBITDA
Assisted Living / Long-Term Care (4)							
Brookdale Senior Living Inc. (NYSE:BKD)	\$6,519.7	(7.3) %	\$3,253.6	\$413.2	12.7 %	2.0 x	15.8 x
The Ensign Group, Inc. (NasdaqGS:ENSG)	5,622.7	8.7	2,246.6	235.2	10.5	2.5	23.9
National HealthCare Corporation (AMEX:NHC)	1,011.4	1.6	994.1	84.8	8.5	1.0	11.9
Capital Senior Living Corporation (NYSE:CSU)	992.2	(2.8)	421.3	40.2	9.5	2.4	24.7
Median		(0.6) %			10.0 %	2.2 x	19.8 x
Hospitals (4)							
HCA Healthcare, Inc. (NYSE:HCA)	\$94,966.7	5.9 %	\$50,146.0	\$9,035.0	18.0 %	1.9 x	10.5 x
Tenet Healthcare Corporation (NYSE:THC)	18,286.2	(3.2)	17,542.0	2,375.0	13.5	1.0	7.7
Universal Health Services, Inc. (NYSE:UHS)	15,720.4	3.7	11,278.1	1,722.1	15.3	1.4	9.1
Community Health Systems, Inc. (NYSE:CYH)	13,417.5	(11.6)	12,075.0	1,001.0	8.3	1.1	13.4
Median		0.3 %			14.4 %	1.3 x	9.8 x
Psychiatric and Behavioral Health (1)							
Acadia Healthcare Company, Inc. (NasdaqGS:ACHC)	\$8,926.1	2.9 %	\$3,090.6	\$532.4	17.2 %	2.9 x	16.8 x
Median		2.9 %			17.2 %	2.9 x	16.8 x
Rehabilitation Facilities (3)							
Encompass Health Corporation (NYSE:EHC)	\$11,872.2	6.9 %	\$4,602.1	\$849.8	18.5 %	2.6 x	14.0 x
Select Medical Holdings Corporation (NYSE:SEM)	9,022.5	8.3	5,415.3	638.0	11.8	1.7	14.1
U.S. Physical Therapy, Inc. (NYSE:USPH)	1,581.5	4.6	431.4	60.7	14.1	3.7	26.1
Median		6.9 %			14.1 %	2.6 x	14.1 x
Surgery Centers (1)							
Surgery Partners, Inc. (NasdaqGS:SGRY)	\$5,224.8	16.3 %	\$1,784.9	\$269.3	15.1 %	2.9 x	19.4 x
Median		16.3 %			15.1 %	2.9 x	19.4 x
Clinical Laboratories (3)							
Laboratory Corporation of America Holdings (NYSE:LH)	\$32,231.0	5.8 %	\$11,474.5	\$1,813.4	15.8 %	2.8 x	17.8 x
Quest Diagnostics Incorporated (NYSE:DGX)	21,841.7	0.5	7,531.0	1,441.0	19.1	2.9	15.2
Chemed Corporation (NYSE:CHE)	7,410.1	7.7	2,020.9	326.3	16.1	3.7	22.7
Median		5.8 %			16.1 %	2.9 x	17.8 x
Diagnostic Imaging (1)							
RadNet, Inc. (NasdaqGM:RDNT)	\$2,196.1	6.3 %	\$1,091.1	\$119.4	10.9 %	2.0 x	18.4 x
Median		6.3 %			10.9 %	2.0 x	18.4 x
Dialysis Services (3)							
Fresenius SE & Co. KGaA (XTRA:FRE)	\$46,528.2	4.0 %	\$36,208.0	\$6,091.0	16.8 %	1.3 x	7.6 x
DaVita Inc. (NYSE:DVA)	23,474.3	9.7	11,523.9	2,450.1	21.3	2.0	9.6
American Renal Associates Holdings, Inc.	991.8	2.6	815.8	115.6	14.2	1.2	8.6
Median		4.0 %			16.8 %	1.3 x	8.6 x
Home Care / Hospice (3)							
Amedisys, Inc. (NasdaqGS:AMED)	\$9,546.3	10.6	1,972.1	208.9	10.6	4.8	NM
LHC Group, Inc. (NasdaqGS:LHCG)	6,803.4	28.9	2,060.0	163.6	7.9	3.3	NM
Addus HomeCare Corporation (NasdaqGS:ADUS)	1,574.6	22.1	735.8	59.5	8.1	2.1	26.5
Median		22.1 %			8.1 %	3.3 x	26.5 x

LSHC sector breakdown: financial detail (cont.)⁽¹⁾


			LTM			EV / LTM	
	Enterprise value (\$MM)	Three-year revenue CAGR	Revenue (\$MM)	EBITDA (\$MM)	EBITDA margin	Revenue	EBITDA
Healthcare Technology (9)							
Veeva Systems Inc. (NYSE:VEEV)	\$41,271.2	27.0 %	\$1,196.4	\$327.8	27.4 %	34.5 x	NM x
Cerner Corporation (NasdaqGS:CERN)	24,056.9	4.3	5,613.8	1,169.9	20.8	4.3	20.6
HealthEquity, Inc. (NasdaqGS:HQY)	6,580.9	49.6	635.0	187.4	29.5	10.4	35.1
Inovalon Holdings, Inc. (NasdaqGS:INOV)	5,554.9	16.0	656.3	179.8	27.4	8.5	30.9
Omniceil, Inc. (NasdaqGS:OMCL)	5,984.1	10.1	906.4	100.9	11.1	6.6	59.3
Allscripts Healthcare Solutions, Inc. (NasdaqGS:MDRX)	3,584.4	1.2	1,718.1	70.0	4.1	2.1	51.2
National Research Corporation (NasdaqGS:NRC)	1,267.0	4.5	130.1	45.7	35.1	9.7	27.7
NextGen Healthcare, Inc. (NasdaqGS:NXGN)	1,265.0	1.3	539.3	32.6	6.0	2.3	38.9
Computer Programs and Systems, Inc. (NasdaqGS:CPSI)	518.2	1.0	268.6	34.5	12.8	1.9	15.0
Median		4.5 %			20.8 %	6.6 x	33.0 x
Telehealth (1)							
Teladoc Health, Inc. (NYSE:TDOC)	13,812.5	65.8 %	716.3	(8.6)	NM %	19.3 x	NM x
Median		65.8 %			NM %	19.3 x	NM x
Biotechnology (6)							
AbbVie Inc. (NYSE:ABBV)	277,820.4	10.7 %	36,227.0	16,729.0	46.2 %	7.7 x	16.6 x
Amgen Inc. (NasdaqGS:AMGN)	172,882.6	1.8	24,301.0	12,115.0	49.9	7.1	14.3
Gilead Sciences, Inc. (NasdaqGS:GILD)	83,581.3	(8.0)	22,174.0	5,564.0	25.1	3.8	15.0
Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN)	46,429.2	18.4	8,693.2	3,028.0	34.8	5.3	15.3
Biogen Inc. (NasdaqGS:BIIB)	46,222.9	7.3	14,487.3	8,049.6	55.6	3.2	5.7
Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN)	36,858.2	17.5	5,536.8	2,911.1	52.6	6.7	12.7
Median		9.0 %			48.0 %	6.0 x	14.6 x
Contract Research and Manufacturing (6)							
IQVIA Holdings Inc. (NYSE:IQV)	56,426.8	11.9 %	10,939.0	1,768.0	16.2 %	5.2 x	31.9 x
West Pharmaceutical Services, Inc. (NYSE:WST)	23,461.7	8.0	1,945.4	441.0	22.7	12.1	NM
Charles River Laboratories International, Inc. (NYSE:CRL)	18,576.8	15.0	2,748.7	610.8	22.2	6.8	30.4
ICON Public Limited Company (NasdaqGS:ICLR)	11,135.6	17.3	2,771.2	470.0	17.0	4.0	23.7
PRA Health Sciences, Inc. (NasdaqGS:PRAH)	11,918.0	19.0	3,094.5	430.5	13.9	3.9	27.7
Medpace Holdings, Inc. (NasdaqGS:MEDP)	5,866.0	32.6	882.0	151.2	17.1	6.7	38.8
Median		16.1 %			17.1 %	5.9 x	30.4 x
Pharmaceuticals (4)							
Pfizer Inc. (NYSE:PFE)	\$265,797.4	(2.0) %	\$49,197.0	\$20,055.0	40.8 %	5.4 x	13.3 x
Merck & Co., Inc. (NYSE:MRK)	215,025.5	5.7	47,194.0	19,046.0	40.4	4.6	11.3
Eli Lilly and Company (NYSE:LLY)	179,464.7	1.4	22,949.8	7,613.3	33.2	7.8	23.6
Bristol-Myers Squibb Company (NYSE:BMJ)	174,441.0	19.9	34,862.0	14,143.0	40.6	5.0	12.3
Median		3.5 %			40.5 %	5.2 x	12.8 x
Tools and Services (8)							
Abbott Laboratories (NYSE:ABT)	\$229,910.5	10.0 %	\$31,444.0	\$7,566.0	24.1 %	7.3 x	30.4 x
Thermo Fisher Scientific Inc. (NYSE:TMO)	209,140.9	11.0	26,248.0	6,961.0	26.5	8.0	30.0
Becton, Dickinson and Company (NYSE:BDX)	92,641.2	11.6	16,917.0	4,570.0	27.0	5.5	20.3
Illumina, Inc. (NasdaqGS:ILMN)	59,414.9	10.5	3,351.0	1,177.0	35.1	17.7	NM
Agilent Technologies, Inc. (NYSE:A)	43,494.9	6.6	5,236.0	1,294.0	24.7	8.3	33.6
Bio-Rad Laboratories, Inc. (NYSE:BIO)	18,847.3	3.2	2,293.6	409.0	17.8	8.2	NM
PerkinElmer, Inc. (NYSE:PKI)	17,043.1	10.6	2,887.3	610.7	21.2	5.9	27.9
Waters Corporation (NYSE:WAT)	20,268.0	1.0	2,278.5	775.1	34.0	8.9	26.1
Median		10.2 %			25.6 %	8.1 x	29.0 x
Commercial Plans (5)							
UnitedHealth Group Incorporated (NYSE:UNH)	\$397,865.7	8.8 %	\$247,811.0	\$26,492.0	10.7 %	1.6 x	15.0 x
Cigna Corporation (NYSE:CI)	122,386.6	56.0	154,629.0	11,529.0	7.5	0.8	10.6
Anthem, Inc. (NYSE:ANTM)	111,468.5	8.7	112,965.0	9,134.0	8.1	1.0	12.2
Humana Inc. (NYSE:HUM)	60,263.1	9.4	70,554.0	5,037.0	7.1	0.9	12.0
Magellan Health, Inc. (NasdaqGS:MGLN)	2,950.1	10.4	7,108.6	197.1	2.8	0.4	15.0
Median		9.4 %			7.5 %	0.9 x	12.2 x
Government Plans (2)							
Centene Corporation (NYSE:CNC)	\$40,555.4	26.5 %	\$88,302.0	\$4,393.0	5.0 %	0.5 x	9.2 x
Molina Healthcare, Inc. (NYSE:MOH)	13,587.1	(2.3)	16,999.0	1,253.0	7.4	0.8	10.8
Median		12.1 %			6.2 %	0.6 x	10.0 x
Payor Services (1)							
CorVel Corporation (NasdaqGS:CRVL)	2,092.7	2.7 %	571.7	76.9	13.5 %	3.7 x	27.2 x
Median		2.7 %			13.5 %	3.7 x	27.2 x

LSHC sector breakdown: financial detail (cont.)⁽¹⁾


	Enterprise value (\$MM)	Three-year revenue CAGR	LTM			EV / LTM		
			Revenue (\$MM)	EBITDA (\$MM)	EBITDA margin	Revenue	EBITDA	
Pharmacy	Retail Pharmacy (3)							
	CVS Health Corporation (NYSE:CVS)	\$172,761.6	13.3 %	\$262,980.0	\$18,256.0	6.9 %	0.7 x	9.5 x
	Walgreens Boots Alliance, Inc. (NasdaqGS:WBA)	87,069.8	3.6	129,832.0	4,945.0	3.8	0.7	17.6
	Rite Aid Corporation (NYSE:RAD)	7,208.6	3.8	22,583.2	628.0	2.8	0.3	11.5
	Median		3.8 %			3.8 %	0.7 x	11.5 x
Physicians / Staffing	Healthcare Staffing (3)							
	AMN Healthcare Services, Inc. (NYSE:AMN)	\$4,737.2	6.7 %	\$2,365.3	\$261.5	11.1 %	2.0 x	18.1 x
	ASGN Incorporated (NYSE:ASGN)	6,558.5	16.1	3,955.2	410.4	10.4	1.7	16.0
	Cross Country Healthcare, Inc. (NasdaqGS:CCRN)	570.3	(0.1)	851.1	23.9	2.8	0.7	23.9
	Median		6.7 %			10.4 %	1.7 x	18.1 x
Physician Practice Management (1)	MEDNAX, Inc. (NYSE:MD)	\$3,793.6	1.6	\$3,504.0	\$458.2	13.1 %	1.1 x	8.3 x
	Median		1.6 %			13.1 %	1.1 x	8.3 x
	Medical Devices and Products (15)							
Medical Devices and Products	Johnson & Johnson (NYSE:JNJ)	\$441,172.1	3.5 %	\$80,503.0	\$27,210.0	33.8 %	5.5 x	16.2 x
	Medtronic plc (NYSE:MDT)	189,101.6	(0.9)	28,913.0	7,736.0	26.8	6.5	24.4
	Danaher Corporation (NYSE:DHR)	204,889.2	1.7	18,033.8	4,457.1	24.7	11.4	46.0
	Stryker Corporation (NYSE:SYK)	106,200.6	5.6	14,070.0	3,538.0	25.1	7.5	30.0
	Boston Scientific Corporation (NYSE:BSX)	68,501.0	5.2	10,157.0	2,233.0	22.0	6.7	30.7
	Baxter International Inc. (NYSE:BAX)	47,140.6	3.5	11,410.0	2,753.0	24.1	4.1	17.1
	Edwards Lifesciences Corporation (NYSE:EW)	59,101.4	10.2	4,321.8	1,342.7	31.1	13.7	44.0
	Zimmer Biomet Holdings, Inc. (NYSE:ZBH)	43,936.4	(3.3)	7,028.0	1,893.7	26.9	6.3	23.2
	ResMed Inc. (NYSE:RMD)	31,313.4	12.7	2,957.0	922.9	31.2	10.6	33.9
	Teleflex Incorporated (NYSE:TFX)	22,300.5	8.4	2,526.9	680.7	26.9	8.8	32.8
	Hologic, Inc. (NasdaqGS:HOLX)	21,502.8	3.4	3,295.4	1,066.0	32.3	6.5	20.2
	STERIS plc (NYSE:STE)	18,993.5	5.2	3,003.0	750.1	25.0	6.3	25.3
	DENTSPLY SIRONA Inc. (NasdaqGS:XRAY)	15,691.2	(3.6)	3,438.5	634.4	18.4	4.6	24.7
	Hill-Rom Holdings, Inc. (NYSE:HRC)	9,555.0	2.9	2,958.5	626.5	21.2	3.2	15.3
	Integer Holdings Corporation (NYSE:ITGR)	3,987.2	(1.3)	1,271.8	248.6	19.5	3.1	16.0
	Median		3.5 %			25.1 %	6.5 x	24.7 x
	Medical Supplies Distribution	Medical Supplies Distribution (6)						
McKesson Corporation (NYSE:MCK)		37,539.3	4.9 %	231,002.0	3,714.0	1.6 %	0.2 x	10.1 x
AmerisourceBergen Corporation (NYSE:ABC)		25,405.8	7.1	186,287.0	2,253.7	1.2	0.1	11.3
Cardinal Health, Inc. (NYSE:CAH)		21,914.1	5.6	152,922.0	2,692.0	1.8	0.1	8.1
Henry Schein, Inc. (NasdaqGS:HSIC)		11,498.7	(8.1)	9,291.0	760.5	8.2	1.2	15.1
Patterson Companies, Inc. (NasdaqGS:PDCO)		3,714.3	(0.6)	5,490.0	268.3	4.9	0.7	13.8
Owens & Minor, Inc. (NYSE:OMI)		3,765.6	(3.6)	8,413.8	193.5	2.3	0.4	19.5
Median		2.2 %			2.0 %	0.3 x	12.6 x	

LSHC sector data


US health care spend⁽¹⁾





US health care spend by payor per capita^{(2) (i)}



US population by age group⁽³⁾



Number of US uninsured by age group⁽⁴⁾



Note:

i) CAGR listed represents total Medicare, Medicaid and Private Health Insurance.

Sources cited

Page 2:

1. Gebreyes, Kulleni; Davis, Andy; Davis, Steve; Shukla, Maulesh; Rush, Brian. "Breaking the cost curve: Deloitte predicts health spending as a percentage of GDP will decelerate over the next 20 years." Deloitte Insights, February 8, 2021.

Page 3:

1. S&P Capital IQ. <https://www.capitaliq.com>, accessed April 26, 2021. Data as of March 31, 2021.
2. Ibid.

Page 4:

1. S&P Capital IQ. <https://www.capitaliq.com>, accessed April 26, 2021. Data as of March 31, 2021.

Page 5:

1. S&P Capital IQ. <https://www.capitaliq.com>, accessed April 26, 2021. Data as of March 31, 2021.

Page 6:

1. S&P Capital IQ. <https://www.capitaliq.com>, accessed April 26, 2021. Data as of March 31, 2021.

Page 7:

1. S&P Capital IQ. <https://www.capitaliq.com>, accessed April 26, 2021. Data as of March 31, 2021.

Page 8:

1. S&P Capital IQ. <https://www.capitaliq.com>, accessed April 26, 2021. Data as of March 31, 2021.

Page 9:

1. Centers for Medicare & Medicaid, Office of the Actuary. "National Health Expenditures and Selected Economic Indicators," 2020.
2. Ibid.
3. US Census Bureau, Current Population Survey, Annual Social and Economic Supplement. "Population by Age and Sex," accessed April 26, 2021.
4. US Department of Health and Human Services. "Early Release of Selected Estimates Based on Data From the 2018 National Health Interview Survey," accessed April 26, 2021.
5. S&P Capital IQ. <https://www.capitaliq.com>, accessed April 26, 2021. Data as of December 31, 2020.

Deloitte Corporate Finance LLC (DCF)

DCF provides deal execution and lead financial advisory services to large corporate, middle market, private equity and venture capital firms. DCF and its affiliates maintain a presence in key US financial centers.

For additional information or to find out more about how DCF can assist the deal initiation and execution process, please contact one of our DCF managing directors:

Phil Colaco, CEO
philcolaco@deloitte.com

+1 704 333 0533

John Deering
jdeering@deloitte.com

+1 704 333 0574

Jamie Lewin
jlewin@deloitte.com

+1 214 840 7057

Justin Silber
jsilber@deloitte.com

+1 404 942 6960

Keith Adams
keadams@deloitte.com

+1 404 631 3455

Lorin DeMordaunt
ldemordaunt@deloitte.com

+1 704 333 0591

James Miller
jamesmiller5@deloitte.com

+1 704 731 8230

Tom Spivey
tspivey@deloitte.com

+1 214 840 7014

Eric Andreozzi
eandreozi@deloitte.com

+1 704 333 0518

Will Frame
wframe@deloitte.com

+1 312 486 4458

Byron Nelson
bynelson@deloitte.com

+1 469 417 2462

Doug Bolt
dbolt@deloitte.com

+1 704 731 7219

Tony Blanchard
anblanchard@deloitte.com

+1 313 396 3738

Lou Paone
lpaone@deloitte.com

+1 704 731 7202

Hector Calzada
hcalzada@deloitte.com

+1 404 631 3015

Bill Kerkam
wkerkam@deloitte.com

+1 980 312 3613

Simon Gisby
sgisby@deloitte.com

+1 212 436 2495

Garett Poston
gposton@deloitte.com

+1 213 593 4544

Matt Preece
mpreece@deloitte.com

+1 704 731 7186

DCF Business Development Group:

Brad Heston

Senior Vice President

bheston@deloitte.com

+1 404 631 3839

John Lindsey

Senior Vice President

jlindsey@deloitte.com

+1 469 417 2147

Bill Pucci

Senior Vice President

wpucci@deloitte.com

+1 973 602 4542

www.investmentbanking.deloitte.com



This newsletter is a periodic compilation of certain completed and announced merger and acquisition activity. Information contained in this newsletter should not be construed as a recommendation to sell or a recommendation to buy any security. Any reference to or omission of any reference to any company in this newsletter shall not be construed as a recommendation to sell, buy or take any other action with respect to any security of any such company. We are not soliciting any action with respect to any security or company based on this newsletter. This newsletter is published solely for the general information of clients and friends of Deloitte Corporate Finance LLC. It does not take into account the particular investment objectives, financial situation, or needs of individual recipients. Certain transactions, including those involving early stage companies, give rise to substantial risk and are not suitable for all investors. This newsletter is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied upon as such. Prediction of future events is inherently subject to both known risks, uncertainties and other factors that may cause actual results to vary materially. We are under no obligation to update the information contained in this newsletter. We and our affiliates and related entities, partners, principals, directors, and employees, including persons involved in the preparation or issuance of this newsletter, may from time to time have "long" and "short" positions in, and buy or sell, the securities, or derivatives (including options) thereof, of companies mentioned herein. The companies mentioned in this newsletter may be: (i) investment banking clients of Deloitte Corporate Finance LLC; or (ii) clients of Deloitte Financial Advisory Services LLP and its related entities. The decision to include any company for mention or discussion in this newsletter is wholly unrelated to any audit or other services that Deloitte Corporate Finance LLC may provide or to any audit services or any services that any of its affiliates or related entities may provide to such company. No part of this newsletter may be copied or duplicated in any form by any means, or redistributed without the prior written consent of Deloitte Corporate Finance LLC.

About Deloitte Corporate Finance LLC

Deloitte Corporate Finance LLC (DCF), a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and member of the [Financial Industry Regulatory Authority \(FINRA\)](#) and the [Securities Investor Protection Corporation \(SIPC\)](#), is an indirect wholly-owned subsidiary of Deloitte Financial Advisory Services LLP and affiliate of Deloitte Transactions and Business Analytics LLP. Investment banking or other services that would require registration as a broker-dealer with the SEC and membership in FINRA would be provided exclusively by DCF. For more information, visit www.investmentbanking.deloitte.com. Please see www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries. Certain services may not be available to attest clients under the rules and regulations of public accounting.

Copyright © 2021 Deloitte Development LLC. All rights reserved.